Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei

Table 3 Analysis of influencing factors for progression-free survival

Prognostic factors	Univariate analysis				Multivariate analysis
	HR		95%CI	P value	HR	95%CI	P value
Sex (female vs male)	0.522	0.143-1.906		0.325		-	-
Age (< 60 vs ≥ 60)	0.630	0.208-1.910		0.414		-	-
Preoperative CEA (increased vs normal)	1.383	0.309-6.193		0.671	-	-	-
Preoperative CA199 (increased vs normal)	1.289	0.446-3.725		0.639
Preoperative CA125 (increased vs normal)	0.245	0.066-0.904		0.035	0.245	0.066-0.904	0.035
KPS (≥ 80 vs < 80)	0.946	0.119-7.493		0.958
CC (2-3 vs 0-1)	0.319	0.100-1.012		0.054	0.351	0.106-1.164	0.087
Pathology (high-grade with signet ring cells vs high-grade vs low-grade)	1.247	0.463-3.357		0.662
Lymph node metastasis (yes vs no)	0.044	0.000-435.823		0.506
Vascular tumor thrombus (yes vs no)	0.044	0.000-435.823		0.506
Nerve invasion (yes vs no)	0.043	0.000-196.970		0.464
VEGF expression (+ vs -)	0.764	0.157-3.712		0.739
CA199 before chemotherapy (increased vs normal)	0.764	0.266-2.197		0.618
CEA before chemotherapy (increased vs normal)	0.743	0.232-2.379		0.616
CA125 before chemotherapy (increased vs normal)	1.401	0.489-4.014		0.530

CEA: Carcinoembryonic antigen; KPS: Karnofsky performance status; CC: Completeness of cytoreduction.